Skip to main content

Table 3 Univariate analysis for prognosis factors

From: Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma

Factors

 

No. of patients

Responder

P

Disease control

P

Median survival (months)

P

Sex

Male

52

13 (25.0%)

0.489

18 (34.6%)

0.114

5.6

0.374

 

Female

13

5 (38.5%)

 

8 (61.5%)

 

7.4

 

Age

≦ 60 years

37

9 (24.3%)

0.580

10 (27.0%)

0.021

5.1

0.050

 

> 60 years

28

9 (32.1%)

 

16 (57.1%)

 

7.0

 

anti-HCV

(-)

45

10 (22.2%)

0.229

12 (26.7%)

0.002

5.4

0.033

 

(+)

20

8 (40.0%)

 

14 (70.0%)

 

7.6

 

HBsAg

(-)

19

7 (36.8%)

0.364

12 (63.2%)

0.025

7.4

0.115

 

(+)

46

11 (23.9%)

 

14 (30.4%)

 

5.6

 

Alcoholism

(-)

33

11 (33.3%)

0.407

15 (45.5%)

0.450

6.0

0.611

 

(+)

32

7 (21.9%)

 

11 (34.4%)

 

5.8

 

ECOG

0

28

10 (35.7%)

0.267a

13 (46.4%)

0.446 a

7.0

0.011a

 

1

22

6 (27.3%)

 

11 (50.0%)

 

6.1

 
 

2

15

2 (13.3%)

 

2 (13.3%)

 

3.6

 

Cirrhosis

(-)

2

0 (0%)

0.999

0 (0%)

0.513

11.5

0.830

 

(+)

63

18 (27.7%)

 

26 (40%)

 

6.0

 

Portal vein thrombosis

(-)

28

8 (28.6%)

0.999

12 (42.9%)

0.799

6.0

0.319

 

(+)

37

10 (27.0%)

 

14 (37.8%)

 

5.5

 

Tumor size

≦ 8 cm

42

15 (35.7%)

0.081

23 (54.8%)

0.001

7.1

0.001

 

> 8 cm

23

3 (13.0%)

 

3 (13.0%)

 

4.2

 

Ascites

(-)

41

10 (24.4%)

0.567

16 (39.0%)

0.999

6.0

0.014

 

(+)

24

8 (33.3%)

 

10 (41.7%)

 

3.6

 

Alpha-fetoprotein

≦ 10000 ng/mL

50

13 (26.0%)

0.743

21 (42.0%)

0.764

7.5

0.098

 

> 10000 ng/mL

15

5 (33.3%)

 

5 (33.3%)

 

4.3

 

Previous treatment

(-)

29

13 (44.8%)

0.011

16 (55.2%)

0.041

6.1

0.750

 

(+)

36

5 (13.9%)

 

10 (27.8%)

 

5.2

 

Extrahepatic metastasis

(-)

27

7 (25.9%)

0.999

8 (29.6%)

0.201

3.7

0.014

 

(+)

38

11 (28.9%)

 

18 (47.4%)

 

7.1

 

Child-Pugh

A

38

9 (23.7%)

0.414

13 (34.2%)

0.309

7.0

0.012

 

B

27

9 (33.3%)

 

13 (48.1%)

 

3.8

 

Okuda stage

I

27

10 (37.0%)

0.173b

14 (51.9%)

0.127b

7.0

0.004c

 

II

28

5 (17.9%)

 

9 (32.1%)

 

5.1

 
 

III

10

3 (30.0%)

 

3 (30.0%)

 

3.1

 

CLIP score

1 or 2

27

10 (37.0%)

0.172b

15 (55.6%)

0.041b

7.0

0.001d

 

3

21

3 (14.3%)

 

5 (23.8%)

 

3,8

 
 

4 or 5

17

5 (29.4%)

 

6 (35.3%)

 

3.5

 

Treatment groups

Regular

27

9 (33.3%)

0.414

14 (51.9%)

0.127

6.0

0.447

 

Split-dose

38

9 (23.7%)

 

12 (31.6%)

 

5.2

 

Courses

1

34

4 (11.8%)

0.005

6 (17.6%)

< 0.001

3.5

< 0.001

 

> 1

31

14 (45.2%)

 

20 (64.5%)

 

7.9

 

Responder

Yes

18

18 (100%)

NC

18 (100%)

NC

9.5

0.004

 

No

47

0

 

8 (17.0%)

 

4.5

 

Disease control

Yes

26

18 (69.2%)

NC

26 (100%)

NC

10.6

< 0.001

 

No

39

0

 

0

 

3.8

 
  1. apatients with ECOG score 0 versus 1 and 2 combined.
  2. bPatients with Okuda stage I versus those with II + III; patients with CLIP score 1 or 2 versus those with score > 2.
  3. cOverall, P = 0.004; Okuda I versus II, P = 0.013; II versus III, P = 0.193.
  4. NC, not calculated
  5. dOverall, P = 0.001: CLIP 1 or 2 versus 3, P = 0.011; CLIP 3 versus >3, P = 0.432.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us